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AbstrACt
Introduction Short interpregnancy interval (IPI) has been 
linked to adverse pregnancy outcomes. WHO recommends 
waiting at least 2 years after a live birth and 6 months after 
miscarriage or induced termination before conception 
of another pregnancy. The evidence underpinning these 
recommendations largely relies on data from low/middle-
income countries. Furthermore, recent epidemiological 
investigations have suggested that these studies may 
overestimate the effects of IPI due to residual confounding. 
Future investigations of IPI effects in high-income 
countries drawing from large, population-based data 
sources are needed to inform IPI recommendations. We 
aim to assess the impact of IPIs on maternal and child 
health outcomes in high-income countries.
Methods and analysis This international longitudinal 
retrospective cohort study will include more than 
18 million pregnancies, making it the largest study to 
investigate IPI in high-income countries. Population-
based data from Australia, Finland, Norway and USA will 
be used. Birth records in each country will be used to 
identify consecutive pregnancies. Exact dates of birth 
and clinical best estimates of gestational length will be 
used to estimate IPI. Administrative birth and health data 
sources with >99% coverage in each country will be 
used to identify maternal sociodemographics, pregnancy 
complications, details of labour and delivery, birth and 
child health information. We will use matched and 
unmatched regression models to investigate the impact of 
IPI on maternal and infant outcomes, and conduct meta-
analysis to pool results across countries.
Ethics and dissemination Ethics boards at participating 
sites approved this research (approval was not required 
in Finland). Findings will be published in peer-reviewed 
journals and presented at international conferences, 
and will inform recommendations for optimal IPI in 
high-income countries. Findings will provide important 
information for women and families planning future 
pregnancies and for clinicians providing prenatal care and 
giving guidance on family planning.
IntroduCtIon 
Interpregnancy interval (IPI), or the time 
from birth to conception of the next preg-
nancy, has been identified as a potentially 
modifiable risk factor linked to adverse peri-
natal outcomes. Currently, WHO recom-
mends that women wait at least 2 years after a 
live birth and 6 months after early pregnancy 
loss before conceiving again to reduce the risk 
of adverse maternal and perinatal outcomes.1 
This recommendation is based on observa-
tional studies, mostly from low/middle-in-
come countries, that have demonstrated 
associations between short IPI and adverse 
pregnancy outcomes,2 most notably maternal 
mortality,3 small for gestational age (SGA), 
term low birth weight (LBW),4 preterm 
prelabour rupture of membranes,5 6 preterm 
strengths and limitations of this study
 ► With data from four countries and over 18 million 
pregnancies, this will be the largest cohort study to 
investigate IPI in high-income countries.
 ► The size of this cohort will allow strict control for 
confounding through matching multiple pregnancies 
within women, and permit the investigation of IPI ef-
fects among subpopulations.
 ► Collaboration between countries and the use of 
individual-level data will minimise methodological 
heterogeneity.
 ► Data items such as socioeconomic status vary be-
tween countries in their completeness and their 
method of measurement, limiting the extent to which 
such variables may be incorporated as covariates.
 ► Data on early pregnancy loss are poorly or inconsis-
tently captured in routine data collection, which may 
result in misclassification of IPI.
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birth (PTB)4 7 8 and birth defects.9 10 Furthermore, long 
IPI has been shown to be associated with higher risk of 
outcomes such as fetal death,11 LBW, PTB, SGA12 and 
pre-eclampsia.11 13 
Several theories have been proposed to explain these 
associations. Short IPIs may leave insufficient time to 
recover from maternal nutrient deficits, which can lead 
to fetal–maternal competition for essential nutrients.14 
This can be exacerbated by lactation15 and malnour-
ishment, in both high-income and low-income coun-
tries.16 17 Short IPIs might also leave insufficient recovery 
time from inflammatory processes from the previous 
pregnancy that extend into the next pregnancy.2 Long 
IPIs may result in the loss of adaptive benefits to the 
mother from a previous birth, resulting in a return to a 
state equivalent to primigravida.17 An alternative hypoth-
esis is that the observed associations between IPI and 
adverse pregnancy outcomes can be explained, at least 
partially, by systematic bias.18 A spurious association 
would result if time to conception were independently 
associated with other factors causally linked to adverse 
pregnancy outcomes in the subsequent pregnancy.19 20 
For example, patterns in IPI are associated with maternal 
age, socioeconomic status (SES), breastfeeding and other 
antenatal, postnatal or postpartum practices.21 22 Further-
more, many factors that can confound the associations 
between IPI and adverse pregnancy outcomes, such 
as psychosocial determinants of health, are difficult to 
measure. Undoubtedly, the greatest challenge for obser-
vational studies is to comprehensively account for such 
confounding factors. High quality studies have adjusted 
for potential confounders, but statistical adjustment is 
rarely complete. Residual unmeasured confounding can 
lead to bias23 of the observed effect of IPI on adverse 
pregnancy outcomes. Importantly, as the mechanisms 
by which IPI affects specific pregnancy outcomes are not 
well understood, direct adjustment cannot be made for 
confounders that remain unknown. Under this scenario, 
the current state of knowledge on the effects of IPI is clin-
ically unreliable.
In recent years, studies have attempted to address the 
issue of bias from unmeasured confounding through a 
matched longitudinal study design.24–26 Longitudinal 
study designs which match pregnancies to the same 
women26 27 can better overcome confounding introduced 
by unknown, unmeasured and inaccurately measured 
factors that tend to vary between mothers but remain 
similar between pregnancies.24 25 28 Findings from these 
studies suggest the effects of IPI reported from unmatched 
models are overestimated. Considerable reductions in the 
U-shape effect of IPI are observed after matching pregnan-
cies to the same women (figure 1),26 indicating support 
for the systematic bias hypothesis. These results provide a 
persuasive argument that some of the IPI effect observed 
in past studies may be attributable to confounders that 
vary between women (eg, heritable/genetic, socioeco-
nomic, recurrent health-related behaviour, unknown/
unmeasured), but can be effectively controlled under a 
longitudinal matched design.
Although these results cast doubt over the adverse 
effects of IPI, the existence of adverse associations with 
perinatal outcomes and the optimal IPI period remains 
unclear due to smaller sample sizes for matched analyses. 
CIs around estimates are typically wider for matched anal-
yses which rely on women having at least two IPIs during 
the study period, particularly for the effects of longer IPI 
(>60 months). In addition, the selection of women with 
more than two pregnancies in matched analyses limits 
generalisability to all women. Several other gaps remain 
in our knowledge around IPI effects (table 1). First, the 
Figure 1 Effects of interpregnancy interval on preterm birth (PTB) and low birth weight (LBW), with and without matching 
pregnancies to the same women, Western Australia, 1980–2010. Figures produced from statistics reported in Ball et al. 201426.
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majority of studies have so far been restricted to low-in-
come and middle-income countries. For example, the 
current WHO recommendation for IPI following early 
pregnancy loss are based on the findings from a single, 
albeit large, study in Latin America,4 and it remains 
unclear as to whether the findings are relevant to high-in-
come countries. Second, some of the most pertinent ques-
tions for women in high-income countries, such as those 
related to obstetric context, have not yet been addressed. 
Additional data from high-income countries and more 
robust results are needed.
study aims
The primary aim of this study is to evaluate the impact 
of IPI on pregnancy outcomes in high-income countries. 
Secondary aims are to:
1. Evaluate the impact of IPI based on obstetric context: 
IPI consequences may differ for women based on ob-
stetric history. For example, optimal IPI may vary for 
women who previously gave birth by caesarean section 
due to risk of uterine rupture after insufficient time for 
the uterine scar to heal.29 The effect of IPI may also vary 
depending on gestational age of the previous birth, 
since longer gestation could be expected to prolong 
the maternal nutrient deficits and inflammatory pro-
cesses implicated in poorer outcomes for the subse-
quent birth, particularly with short IPI. Furthermore, 
recommendations of IPI after stillbirth require specific 
attention.30 Pregnancy intervals for women following 
a stillbirth or neonatal loss are approximately 1 year 
shorter than intervals for women without a loss.31 32 It 
has been speculated that this is due to parents wish-
ing to counter the emotional loss of their infant or 
to minimise the delay in having a baby.33 However, a 
survey of obstetricians regarding the timing of preg-
nancy following pregnancy loss found approximately 
two-thirds of obstetricians endorse women waiting less 
than 6 months after stillbirth before trying to conceive 
a new pregnancy.34 This is incongruous with WHO IPI 
recommendations that women wait at least 6 months 
after pregnancy loss.
2. Evaluate the impact of IPI based on sociodemographic 
context: The IPI recommendations generated by this 
study may be most beneficial for those populations for 
whom we know short IPI and high parity (large family 
size) is prevalent. Within high-income countries, both 
family size and the IPI distribution can vary markedly 
according to race/ethnicity and SES.35 36 In this study, 
we will investigate the effects of IPI among women from 
different socioeconomic and racial/ethnic groups in 
multiple high-income countries.
3. Evaluate the potential influence of maternal age on the 
effect of IPI on pregnancy outcomes: In high-income 
countries, age at childbirth overall is increasing, with 
later age at first birth.37–39 Systematic reviews conclude 
that increased maternal age is associated with greater 
risk of a wide range of adverse obstetric outcomes,40 
including perinatal mortality,41 PTB and LBW42 and 
pregnancy intervention, particularly caesarean sec-
tion.43 In this study, we will test the hypothesis that 
there is an interaction between increased maternal age 
and IPI on the risk of adverse pregnancy outcomes. 
For each year of maternal age (ie, maternal age at first 
observed birth in the study period) and for different 
IPIs, we will calculate the risk of adverse pregnancy 
outcomes. This will provide valuable information on 
any combined risks of maternal age and IPI for older 
women conceiving their second (or later) child.
MEthods And AnAlysIs
study design and population
We will conduct a longitudinal retrospective cohort 
study on the effects of IPI on maternal and child health 
outcomes using individual-level records with near 
complete coverage of all births (>99%) in Australia 
(Western Australia (WA) and New South Wales (NSW)), 
Finland, Norway and the USA (California) (table 2).
We will conduct analyses using unmatched (all women) 
and matched approaches. By matching pregnancies to 
the same women, we will account for individual-level 
confounders (known and unknown) that remain stable 
Table 1 Significant gaps in knowledge needed to inform 
recommendations for optimal interpregnancy interval 
(IPI) recommendations in high-income countries
Knowledge gap Description
What are the IPI effects after 
eliminating confounding from 
between-women comparisons?
Few past studies have addressed 
confounding by matching 
pregnancies to the same women.1
Can IPI effects be observed 
later in childhood?
No past studies have investigated 
outcomes beyond the neonatal 
period, such as hospitalisation in 
early childhood.
What are the optimal IPIs for 
which risks are minimised?
Although knowledge of harmful 
IPIs is important, health is 
optimised by identification of 
optimal IPIs for which risks are 
minimised.1
What are the IPI effects for a 
wide range of outcomes of both 
the mother and child?
The vast majority of studies to 
date investigate a single endpoint 
for a single group (mother or 
child). IPI recommendations 
require a wide range of health 
endpoints for both mother and 
child.
What are the context-specific 
IPI recommendations?
Guideline IPIs are needed for 
subpopulations ,for example, for 
women who attempt labour after 
caesarean birth to avoid uterine 
rupture,29 and for women after 
stillbirth due to elevated risk of 
recurrence or faster maternal 
recovery. For women at advanced 
maternal age, delaying child 
birth even further due to IPI 
recommendations comes at the 
cost of competing risks of age-
related morbidities.49
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between pregnancies. The effect of IPI from matched 
and unmatched analyses will be compared. The study’s 
population will consist of more than 18 million births, 
which will be the largest IPI study for high-income coun-
tries. The size of this cohort offers several advantages, as 
it allows us to: (1) investigate IPI effects among subpop-
ulations, and (2) ensure the best possible control for 
confounding. Where within-mother matching is not 
possible (eg, when studying effect modification, sample 
size in individual data categories becomes reduced), we 
will match on propensity scores.44
Inclusion criteria
Women with two or more consecutive pregnancies will be 
included in the study. The target population for inference 
includes women with >1 birth during their life course. 
IPI is not relevant for women who have only one birth. 
Given that matching pregnancies to the same women 
requires >1 pregnancy interval per woman, the cohort for 
matched analyses will be restricted to women who have 
two or more births during the study period. The 20-year 
to 30-year study period ensures sufficient follow-up 
to observe final family size. Birth status (live born vs 
stillborn), plurality (singleton vs multiple) and maternal 
age will inform inclusion criteria for specific hypotheses.
definition of IPI
IPI will be defined as the length of time between the start 
of the index pregnancy (birth date minus gestational 
length) and the birth date of the preceding pregnancy. IPI 
will be classified using integer months and categorised as: 
0–5, 6–11, 12–17, 18–23, 24–59, 60–119 and ≥120 months, 
with 18–23 months used as the referent group.26 These 
intervals share endpoints consistent with recommen-
dations of past studies and WHO recommendations. In 
addition, IPI will be considered as a continuous variable 
for assessment of optimal IPI.
IPI-relevant health outcomes
Based on a review of the current literature, we identi-
fied a set of clinically significant IPI-relevant endpoints, 
contexts and competing risks that can be investigated 
accurately and reliably (see online supplementary table 
S1). We classified the primary IPI-relevant endpoints into 
the following two categories: PTB; and fetal growth restric-
tion based on the definitions of SGA and LBW. Additional 
Table 2 Description of cohort and data sources used to identify a cohort of births in four high-income countries
Location California, USA Finland Norway
New South Wales, 
Australia
Western Australia, 
Australia
Time period 1991–2010 1987–2017 1980–2016 1994–2016 1980–2015
Data source Office of Statewide 
Health Planning and 
Development (OSHPD)
National Institute for 
Health and Welfare 
(THL), Medical Birth 
Register
Norwegian Institute of 
Public Health, Medical 
Birth Registry
NSW Perinatal Data 
Collection, NSW 
Ministry of Health
WA Midwives Data 
Collection, WA 
Department of Health
Information available Maternal 
characteristics and 
health conditions; 
smoking and 
BMI (2007–2010); 
pregnancy and labour 
conditions, antenatal 
hospitalisations, 
information on delivery 
and birth outcomes; 
gestational age based 
on LMP estimate 
(obstetric estimate 
available for years 
2007–2010)
Maternal 
characteristics and 
health conditions; 
smoking; pregnancy 
and labour 
complications; 
pregnancy history; 
details of antenatal 
care; information on 
delivery and birth 
outcomes; health of 
infant at discharge or 
7 days
Maternal 
characteristics and 
health conditions; 
pregnancy and 
labour complications; 
medication use during 
pregnancy; birth 
outcomes; diagnoses 
of congenital 
abnormalities; 
parental occupation 
and smoking; births 
following assisted 
conception
Maternal 
characteristics and 
health conditions; 
smoking; pregnancy 
and labour 
complications; details 
of labour; birth 
outcomes; congenital 
anomalies, infant and 
child health outcomes
Maternal 
characteristics and 
health conditions; 
smoking; pregnancy 
and labour 
complications; details 
of labour; birth 
outcomes; congenital 
anomalies, infant and 
child health outcomes
Scope of notified 
births
All live births 
and stillbirths 
with gestational 
length ≥20 weeks
All live births 
and stillbirths 
with gestational 
length ≥22 weeks or 
birth weight ≥500 g
All pregnancies ending 
after week 12 from 
2002 onwards (from 
week 16 from 1980 to 
2001)
Gestational 
length ≥20 weeks or 
birth weight ≥400 g
Gestational 
length ≥20 weeks or 
birth weight ≥400 g
Linkage methods Probabilistic linkage 
based on maternal 
descriptors
Deterministic linkage 
of mother based on 
personal ID
Deterministic linkage 
of mother based on 
personal ID
Probabilistic linkage 
based on maternal 
descriptors
Probabilistic linkage 
based on maternal 
descriptors
Total births 10.9 million 1.8 million 2.1 million 2.2 million 1.2 million
Benchmark neonatal 
morbidity indicators
10.5% PTB (LMP 
estimate)
6.4% LBW
5.8% PTB
4.3% LBW
5.7% PTB
3.4% LBW
5.4% PTB
4.4% LBW
5.3% PTB
5.3% LBW
BMI, body mass index; LBW, low birth weight; LMP, last menstrual period; PTB, preterm birth.
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endpoints include congenital anomaly; complications of 
pregnancy and labour; infant and child health outcomes; 
and perinatal, infant and maternal mortality.
data sources
Cohorts will be assembled from linked birth cohort files in 
California with Office of Statewide Health Planning and 
Development maternal and infant hospital discharge data 
(USA: 1991–2010); the National Institute for Health and 
Welfare (THL), Medical Birth Register (Finland: 1987–
2017); the Norwegian Institute of Public Health, Medical 
Birth Registry (Norway: 1980–2015); the NSW Perinatal 
Data Collection, NSW Ministry of Health (Australia: 1994–
2016); and the WA Midwives Data Collection, WA Depart-
ment of Health (Australia: 1980–2015) (table 2). Coverage 
is >99% of births for each country/jurisdiction. IPIs for 
each data source will be derived (figure 2), and maternal 
characteristics and health conditions, pregnancy complica-
tions, details of labour and childbirth, birth outcomes and 
mortality will be identified (see online supplementary table 
S1). Some sites will have access to additional linked hospital 
and child development data, offering the opportunity to 
explore the impact on additional maternal and child health 
outcome measures, including congenital anomalies (WA, 
NSW, Norway, Finland) and hospital admissions (WA, NSW, 
Finland).
data deidentification and secure storage
Deidentified data from California and Finland will be 
retained and held securely at those sites; deidentified 
data from Norway, WA and NSW will be transferred 
to and stored at the School of Public Health, Curtin 
University. Project data will be electronically stored 
on a secure server, which is backed up daily to prevent 
any unintentional data loss. The research environment 
includes a variety of security controls to restrict unautho-
rised access—these include access controls, role-based 
delegations, encryption, firewalls and physical access 
restrictions (authorised access to server rooms and 
research offices is restricted by key). Automatic screen 
locking will occur on electronic devices after 5 min 
of inactivity. Data will not be stored or used in public 
terminals. No paper-based or portable electronic media 
storage of data will take place.
statistical methods
Matched and unmatched logistic regression will be used 
to investigate all maternal and child health outcomes 
(see online supplementary table S1). For primary anal-
yses, mother ID will be used as the matching variable 
to identify strata. This method ensures that the results 
will be based entirely on within-women (not between-
women) comparisons, minimising the need for addi-
tional adjustment and is the standard statistical method 
for matched studies. We will explicitly adjust for factors 
of the index pregnancy that do/can change between 
pregnancies. Specifically, we will adjust for maternal age 
(categorical variable: 14–19, 20–24, 25–29, 30–34, 35–39 
and ≥40 years), parity (categorical) and conception year 
(non-linear spline). Due to differences between coun-
tries in the completeness and method of measurement 
of SES (or maternal education as a proxy), adjustment 
for SES will not be possible when data are pooled across 
countries, but may be undertaken when analyses are 
conducted using single-country data sets.
Matched analyses will be undertaken to address secondary 
aims, where possible. In circumstances where within-mother 
matching is not feasible or not possible (eg, subpopulations 
with small sample sizes which would be further restricted 
by requiring more than two consecutive pregnancies per 
mother), unmatched models or alternative matching 
methods will be used (eg, propensity score stratification; 
sibling-matched methods using a single IPI).8 44 45
Figure 2 Distribution of interpregnancy interval following a live birth, by country/state—1980–2016.
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Analyses will first be applied to each site’s data individ-
ually. The analytic approach and statistical code used for 
data sets held at Curtin University (WA, NSW, Norway) will 
be sent to the other sites (California, Finland) to replicate 
analyses, allowing standardisation and minimising meth-
odological heterogeneity between countries.46 Meta-anal-
ysis47 will be used to combine adjusted ORs obtained from 
each data source into a single pooled estimate general-
isable to high-income countries. Heterogeneity between 
countries will be investigated with the I2 statistic.48
Patient and public involvement
A reference group of consumer health representatives 
(Healthy Pregnancies Reference Group) has been estab-
lished, and will meet twice-yearly to provide a commu-
nity perspective on this research. The reference group 
will provide advice regarding the aims of the research; 
language, including lay summaries; links between 
consumers, the community and the researchers; and 
advocacy on behalf of consumers and the community. 
The reference group will also contribute consumer 
perspectives on potential utilisation of the research find-
ings, such as the identification of factors that may influ-
ence IPI (see online supplementary table S2), with the 
intention to inform further primary research in this area.
EthICs And dIssEMInAtIon
human research ethics committee approval
This research has ethics approval from ethics committees 
at participating sites. Each committee provided a waiver 
of consent for participants. For Finland, ethical approval 
was not required.
Intended publications and research dissemination
Data sets generated and/or analysed during the current 
study are not publicly available due to data confidentiality 
agreements with data custodians. Results generated by the 
research will be made publicly available at the summary 
level. Standalone manuscripts addressing primary and 
secondary aims will be published in peer-reviewed jour-
nals. Results will also be presented at relevant perinatal 
and epidemiological conferences. Findings will be used 
to develop guidelines for IPI as a potentially modifiable 
risk factor linked to adverse perinatal outcomes, specifi-
cally for women in high-income countries.
dIsCussIon
This study will inform new IPI recommendations for 
women in high-income countries. Recommendations 
will be specific to obstetric and socioeconomic context. 
By combining record-linked perinatal data from multiple 
countries—Australia, Finland, Norway and the USA—this 
study will achieve the largest sample of high-quality health 
data in high-income countries. Novel methodology, 
matching pregnancies to the same women, will achieve 
the best control for confounding of any study to date.
This international cohort approach offers several 
advantages. Large sample sizes are required to undertake 
matched analyses with adequate statistical power to detect 
clinically meaningful differences between IPIs. Prospec-
tive studies of this size are infeasible. This study can only 
be achieved using linked perinatal data within an inter-
national collaboration. Collaboration to standardise 
methods between countries will also minimise method-
ological heterogeneity in pooled analyses. Furthermore, 
this research has the potential to be extended by broad-
ening the collaboration to incorporate additional data 
sets. The minimum data requirements for contributing 
to this project are: (1) unique identifier for mothers to 
link multiple pregnancies; (2) mother’s date of birth; (3) 
child’s date of birth; (4) child’s gestational length; and (5) 
other birth and early childhood outcomes as described in 
online supplementary table S1. Researchers interested in 
joining this collaboration are encouraged to contact us 
through the corresponding author.
This information is essential for supporting family 
planning, both at the patient and provider level. 
Evidence-based recommendations for IPI for women in 
high-income countries are useful for assisting families 
when planning future pregnancies and for clinicians 
when providing intrapregnancy counselling.
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